Apitegromab Adds Muscle-Directed Therapy in SMA Care

What the approval adds

Apitegromab is the first FDA-approved spinal muscular atrophy treatment directed at muscle loss rather than the underlying deficiency of survival motor neuron, or SMN, protein. It inhibits activation of myostatin, a negative regulator of skeletal-muscle growth, and is intended to complement an existing SMN2-targeted treatment.

That distinction matters. Nusinersen and risdiplam increase production of functional SMN protein by modifying SMN2 messenger-RNA processing. Apitegromab works downstream, where longstanding denervation, reduced activity and impaired muscle development may continue to limit strength and motor performance despite disease-modifying treatment.

The FDA’s September 11, 2026 decision establishes a combination-treatment population: patients must be at least 2 years old and already receiving an SMN2-targeted therapy. The approval does not establish apitegromab as a substitute for nusinersen or risdiplam, as monotherapy, or for children younger than 2 years.

Prior treatment with onasemnogene abeparvovec requires a separate eligibility assessment. Gene replacement is directed at SMN1, not SMN2, so previous gene therapy alone does not necessarily satisfy wording that requires current SMN2-targeted treatment. The complete prescribing information and payer criteria should determine whether a patient receiving risdiplam or nusinersen after gene therapy falls within the approved use.

Evidence supporting a complementary mechanism

The pivotal SAPPHIRE study was a randomized, double-blind, placebo-controlled phase 3 trial in 188 nonambulatory participants aged 2 to 21 years with later-onset spinal muscular atrophy. Participants were receiving stable nusinersen or risdiplam. The study compared intravenous apitegromab at 10 or 20 mg/kg every four weeks with placebo over 52 weeks; those research regimens should not be used in place of the approved prescribing information.

The prespecified primary efficacy population comprised children aged 2 to 12 years. In that group, the pooled apitegromab doses produced an adjusted 1.8-point advantage over placebo in change from baseline on the Hammersmith Functional Motor Scale–Expanded at week 52, with a reported p value of 0.0192. This scale evaluates activities such as rolling, sitting, kneeling, standing and stepping, although the relevance of a group-level difference varies with baseline function and individual goals.

The randomized design supports a causal interpretation for the measured 52-week treatment effect in the studied population. It does not show that apitegromab restores lost motor neurons, reverses established contractures or eliminates respiratory, orthopedic and nutritional complications. Nor does it establish the same magnitude of benefit in ambulatory patients, adults older than those enrolled, children younger than 2 years or patients not receiving background SMN2 therapy.

The earlier TOPAZ study evaluated apitegromab in patients with type 2 or type 3 spinal muscular atrophy and informed the subsequent phase 3 program. Together, the studies tested a layered therapeutic strategy: maintain SMN-directed treatment while targeting the muscle’s capacity to respond. The FDA decision indicates that the agency judged the overall benefit-risk profile adequate for the labeled population; the complete label remains the controlling source for administration, warnings, adverse reactions and monitoring requirements.

How multidisciplinary care may change

The practical change is not simply the addition of another prescription. SMA teams now have to decide when residual weakness or loss of motor potential warrants a second disease-modifying mechanism, while distinguishing potentially modifiable muscle impairment from fixed contracture, skeletal deformity, pain, fatigue or progression driven by motor-neuron loss.

A baseline assessment should document motor function with an age- and ability-appropriate instrument, together with patient-prioritized activities such as independent sitting, transfers, wheelchair control, self-feeding or endurance during daily care. Repeating the same validated measure at clinically meaningful intervals is more informative than switching scales or relying on an isolated office impression.

Physical and occupational therapists remain central. A therapy-related gain in muscle capacity may not translate automatically into useful movement when joint range, positioning, equipment or learned compensations are limiting. Rehabilitation should therefore connect measurable motor changes to function without assuming that more exercise is always beneficial or that a short-term plateau represents treatment failure.

Pulmonary, nutritional and orthopedic care does not become less important. Apitegromab is not a respiratory-support intervention, does not correct swallowing dysfunction and does not treat scoliosis or hip instability. Respiratory surveillance, vaccination, airway-clearance planning, sleep assessment, growth and nutrition review, bone health, seating and contracture management should continue according to phenotype and clinical need.

The approval also creates operational demands. Infusion capacity, travel burden, venous access, coordination with intrathecal nusinersen or daily oral risdiplam, laboratory and adverse-event monitoring specified by the label, and payer authorization may all affect feasibility. Shared decisions should account for treatment burden and the functional outcomes that matter to the patient, not only statistical significance in the pivotal trial.

Important limits and unanswered questions

SAPPHIRE was industry sponsored and studied a selected trial population under protocol-defined conditions. The primary analysis focused on children aged 2 to 12 years, even though enrollment extended through age 21. Evidence is consequently less direct for older adolescents, adults, ambulatory patients, people with advanced contractures, and those whose background treatment or clinical status differs from the trial population.

Follow-up of 52 weeks defines the controlled efficacy evidence but cannot resolve durability over many years, the best time to begin treatment, or whether early addition prevents otherwise irreversible loss of function. Comparative effectiveness between background nusinersen and risdiplam has not been established by the approval, and the trial was not designed to determine whether one provides a better platform for apitegromab.

Postmarketing evidence will need to characterize uncommon adverse effects, long-term muscle and tendon outcomes, real-world treatment persistence, and effectiveness across a broader range of ages and SMA phenotypes. Registries should also capture outcomes important to families and health systems, including caregiver assistance, hospitalization, respiratory support, participation and treatment burden.

Questions clinicians ask

Is every patient with SMA aged 2 years or older eligible?

No. The approved population is defined not only by age and diagnosis but also by current use of an SMN2-targeted treatment. The complete FDA prescribing information should be checked for additional clinical, administration or safety provisions before treatment is considered.

Should apitegromab replace nusinersen or risdiplam?

No. The evidence and approval support apitegromab as an add-on to an SMN2-targeted treatment. Stopping background therapy would move outside the combination strategy evaluated in SAPPHIRE and should not be inferred from a muscle-directed approval.

How should response be assessed in routine care?

Use a consistent, validated motor scale suited to the patient’s age and functional level, then pair it with individualized goals such as transfers, sitting, upper-limb use or endurance. Respiratory, swallowing, orthopedic and participation outcomes remain relevant because a motor-scale change does not capture the full burden of SMA.

Does prior gene therapy establish eligibility?

Not by itself. Onasemnogene abeparvovec replaces SMN1 and is not an SMN2-targeted treatment. A patient who previously received gene therapy may require confirmation that their current regimen and clinical circumstances meet the approved indication, particularly if they are also receiving nusinersen or risdiplam.

References

1. Rare Disease Drug Approvals — U.S. Food and Drug Administration, 2026
2. A Study of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy (SAPPHIRE) — ClinicalTrials.gov, 2021
3. A Study of Apitegromab in Patients With Spinal Muscular Atrophy (TOPAZ) — ClinicalTrials.gov, 2019
4. Spinal Muscular Atrophy — National Institute of Neurological Disorders and Stroke, 2025